Clinical trial · Interventional
Biomolecular Analysis for Predicting Response to Regorafenib
Tumor Biomolecular Analysis for Defining Predictive Factors for Response to Regorafenib in Recurrent Glioblastoma
NCT05759195CI-TRIAL-00087190RegoReccompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study envisages NGS analysis on tumor tissue from patients treated with regorafenib for recurrent glioblastoma as per standard care, with the aim to identify predictive biomarkers for response.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
| Glioblastoma, IDH-wildtype | Glioblastoma, IDH-Wildtype | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biomolecular tumor analysis | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Biomolecular tumor analysis
- description
- NGS, IHC, methylome and other molecular studies
- interventionNames
- Diagnostic Test: Biomolecular tumor analysis
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- through study completion, an average of 3 years
- description
- Interval between tumor diagnosis and death or end of follow-up
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. recurrent glioblastoma after surgery and chemoradiation with temozolomide; 2. indication to treatment with regorafenib per standard of care; 3. written informed consent. Exclusion Criteria: None.
References
Publications (0)
Data not yet available
No reference posted for this study.